Invesco Ltd. Boosts Holdings in Teleflex Incorporated (NYSE:TFX)

Invesco Ltd. raised its position in shares of Teleflex Incorporated (NYSE:TFX - Free Report) by 48.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,068,593 shares of the medical technology company's stock after purchasing an additional 347,003 shares during the quarter. Invesco Ltd. owned 2.30% of Teleflex worth $190,188,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Vontobel Holding Ltd. boosted its holdings in shares of Teleflex by 21.9% in the 4th quarter. Vontobel Holding Ltd. now owns 1,393 shares of the medical technology company's stock worth $248,000 after purchasing an additional 250 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Teleflex by 14.3% in the third quarter. JPMorgan Chase & Co. now owns 155,158 shares of the medical technology company's stock valued at $38,374,000 after acquiring an additional 19,466 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its holdings in Teleflex by 5.2% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 108,231 shares of the medical technology company's stock worth $19,263,000 after buying an additional 5,322 shares during the period. Lecap Asset Management Ltd. bought a new stake in Teleflex during the fourth quarter valued at about $729,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Teleflex by 35.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,875 shares of the medical technology company's stock valued at $1,053,000 after buying an additional 1,527 shares in the last quarter. Hedge funds and other institutional investors own 95.62% of the company's stock.

Teleflex Stock Up 1.0 %

NYSE TFX traded up $1.28 on Thursday, reaching $129.49. The company had a trading volume of 90,716 shares, compared to its average volume of 617,336. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.39 and a current ratio of 2.42. The firm has a market capitalization of $6.00 billion, a price-to-earnings ratio of 25.71, a price-to-earnings-growth ratio of 1.73 and a beta of 1.19. Teleflex Incorporated has a 1-year low of $124.66 and a 1-year high of $249.91. The company's fifty day moving average is $145.36 and its 200-day moving average is $179.57.

Teleflex (NYSE:TFX - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical technology company reported $3.89 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.86 by $0.03. The company had revenue of $795.40 million during the quarter, compared to analysts' expectations of $813.24 million. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. On average, research analysts forecast that Teleflex Incorporated will post 13.98 earnings per share for the current fiscal year.

Teleflex Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, March 17th. Stockholders of record on Friday, March 7th were paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 1.05%. The ex-dividend date was Friday, March 7th. Teleflex's payout ratio is currently 95.77%.

Analyst Ratings Changes

TFX has been the topic of several research analyst reports. Morgan Stanley dropped their price target on Teleflex from $275.00 to $191.00 and set an "overweight" rating on the stock in a research note on Wednesday, March 5th. Needham & Company LLC reaffirmed a "hold" rating on shares of Teleflex in a research note on Wednesday, March 12th. Piper Sandler reaffirmed a "neutral" rating and set a $140.00 target price (down from $255.00) on shares of Teleflex in a research note on Friday, February 28th. Citizens Jmp cut shares of Teleflex from an "outperform" rating to a "market perform" rating in a research report on Thursday, February 27th. Finally, Raymond James downgraded Teleflex from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Teleflex presently has a consensus rating of "Hold" and an average price target of $169.63.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.